Centre for Observational Research & Data Sciences, Bristol-Myers Squibb, Uxbridge, UK.
Statistics, Global Biometrics and Data Management, Pfizer Inc., New York City, NY, USA.
J Comp Eff Res. 2020 Jun;9(9):603-614. doi: 10.2217/cer-2020-0013. Epub 2020 Mar 18.
After decades of warfarin being the only oral anticoagulant (OAC) widely available for stroke prevention in atrial fibrillation, four direct OACs (apixaban, dabigatran, edoxaban and rivaroxaban) were approved after demonstrating noninferior efficacy and safety versus warfarin in randomized controlled trials. Comparative effectiveness research of OACs based on real-world data provides complementary information to randomized controlled trials. Propensity score matching and inverse probability of treatment weighting are increasingly popular methods used to address confounding by indication potentially arising in comparative effectiveness research due to a lack of randomization in treatment assignment. This review describes the fundamentals of propensity score matching and inverse probability of treatment weighting, appraises differences between them and presents applied examples to elevate understanding of these methods within the atrial fibrillation field.
在华法林成为房颤卒中预防唯一口服抗凝药(OAC)的几十年后,四项直接 OAC(阿哌沙班、达比加群、依度沙班和利伐沙班)在随机对照试验中显示出与华法林非劣效性和安全性后获得批准。基于真实世界数据的 OAC 比较有效性研究为随机对照试验提供了补充信息。倾向评分匹配和逆概率治疗加权是日益流行的方法,用于解决由于治疗分配缺乏随机化而在比较有效性研究中可能出现的指示性混杂。本综述描述了倾向评分匹配和逆概率治疗加权的基本原理,评价了它们之间的差异,并提供了应用实例,以提高在房颤领域对这些方法的理解。